Skip to main content
Erschienen in: Inflammation Research 1/2021

18.11.2020 | COVID-19 | Review Zur Zeit gratis

Histamine receptors and COVID-19

verfasst von: Madeleine Ennis, Katerina Tiligada

Erschienen in: Inflammation Research | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

Reports that the over-the-counter histamine H2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from April 2020. We, therefore, examined reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists.

Methods

A systematic literature search was performed by 19 September 2020, and updated on 28 October 2020, in PubMed, Scopus, Cochrane Library and Google Scholar using (COVID-19 OR coronavirus OR SARS-CoV-2) AND (histamine antagonist OR famotidine OR cimetidine). ClinicalTrials.gov was searched for COVID-19 and (famotidine or histamine).

Results

Famotidine may be a useful addition in COVID-19 treatment, but the results from prospective randomized trials are as yet awaited. Bioinformatics/drug repurposing studies indicated that, among several medicines, H1 and H2 receptor antagonists may interact with key viral enzymes. However, in vitro studies have to date failed to show a direct inhibition of famotidine on SARS-CoV-2 replication.

Conclusions

Clinical research into the potential benefits of H2 receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-centre clinical trials. The positive effects of famotidine may be due to H2 receptor-mediated immunomodulatory actions on mast cell histamine–cytokine cross-talk, rather than a direct action on SARS-CoV-2.
Literatur
1.
Zurück zum Zitat Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–326.PubMedPubMedCentral Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–326.PubMedPubMedCentral
2.
Zurück zum Zitat Baj J, KarakułaJuchnowicz H, Teresiński G, et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J Clin Med. 2020;9:1753.PubMedCentral Baj J, KarakułaJuchnowicz H, Teresiński G, et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J Clin Med. 2020;9:1753.PubMedCentral
3.
Zurück zum Zitat Valle C, Martin B, Shannon A, et al. Drugs against SARS-CoV-2: What do we know about their mode of action? Rev Med Virol. 2020;e2143. Valle C, Martin B, Shannon A, et al. Drugs against SARS-CoV-2: What do we know about their mode of action? Rev Med Virol. 2020;e2143.
4.
Zurück zum Zitat Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.PubMedPubMedCentral Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.PubMedPubMedCentral
5.
Zurück zum Zitat Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766–88.PubMedPubMedCentral Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766–88.PubMedPubMedCentral
6.
Zurück zum Zitat Kandeel M, Abdelrahman AHM, Oh-Hashi K, et al. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. J Biomol Struct Dyn. 2020;1–8. Kandeel M, Abdelrahman AHM, Oh-Hashi K, et al. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. J Biomol Struct Dyn. 2020;1–8.
7.
Zurück zum Zitat Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020;9:331.PubMedCentral Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020;9:331.PubMedCentral
8.
Zurück zum Zitat Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–68.PubMedPubMedCentral Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–68.PubMedPubMedCentral
9.
Zurück zum Zitat Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(271–80):e8. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(271–80):e8.
10.
Zurück zum Zitat Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(914–21):e10. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(914–21):e10.
11.
Zurück zum Zitat Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells. 2020;9:1267.PubMedCentral Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells. 2020;9:1267.PubMedCentral
12.
Zurück zum Zitat Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499–504.PubMedPubMedCentral Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499–504.PubMedPubMedCentral
13.
Zurück zum Zitat Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785–97.PubMedPubMedCentral Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785–97.PubMedPubMedCentral
14.
Zurück zum Zitat Hashemian SM, Farhadi T, Velayati AA. A review on remdesivir: A possible promising agent for the treatment of COVID-19. Drug Des Devel Ther. 2020;14:3215–22.PubMedPubMedCentral Hashemian SM, Farhadi T, Velayati AA. A review on remdesivir: A possible promising agent for the treatment of COVID-19. Drug Des Devel Ther. 2020;14:3215–22.PubMedPubMedCentral
15.
Zurück zum Zitat Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020; published online ahead of print. Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020; published online ahead of print.
16.
Zurück zum Zitat Meyer-Almes FJ. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. Comput Biol Chem. 2020;88:107351.PubMedPubMedCentral Meyer-Almes FJ. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. Comput Biol Chem. 2020;88:107351.PubMedPubMedCentral
17.
Zurück zum Zitat Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2020;177:469–89.PubMed Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2020;177:469–89.PubMed
18.
Zurück zum Zitat Borriello F, Iannone R, Marone G. Histamine release from mast cells and basophils. Handb Exp Pharmacol. 2017;241:121–39.PubMed Borriello F, Iannone R, Marone G. Histamine release from mast cells and basophils. Handb Exp Pharmacol. 2017;241:121–39.PubMed
19.
Zurück zum Zitat Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol. 2018;142:381–93.PubMed Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol. 2018;142:381–93.PubMed
20.
Zurück zum Zitat Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20:4241.PubMedCentral Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20:4241.PubMedCentral
22.
Zurück zum Zitat Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020;S0149-2918(20)30357-X. Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020;S0149-2918(20)30357-X.
24.
Zurück zum Zitat Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, Famotidine Research Group. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020;159:1129–31.PubMed Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, Famotidine Research Group. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020;159:1129–31.PubMed
25.
Zurück zum Zitat Janowitz T, Gablenz E, Pattinson D, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020;69:1592–7.PubMed Janowitz T, Gablenz E, Pattinson D, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020;69:1592–7.PubMed
26.
Zurück zum Zitat Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020;115:1617–23.PubMed Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020;115:1617–23.PubMed
33.
Zurück zum Zitat Hogan RB II, Hogan RB III, Cannon T, et al. Dual-histamine blockade with cetirizine—famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020;63:101942. Hogan RB II, Hogan RB III, Cannon T, et al. Dual-histamine blockade with cetirizine—famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020;63:101942.
35.
Zurück zum Zitat Rogosnitzky M, Berkowitz E, Jadad AR. Delivering benefits at speed through real-world repurposing of off-patent drugs: The COVID-19 pandemic as a case in point. JMIR Public Health Surveill. 2020;6:e19199.PubMedPubMedCentral Rogosnitzky M, Berkowitz E, Jadad AR. Delivering benefits at speed through real-world repurposing of off-patent drugs: The COVID-19 pandemic as a case in point. JMIR Public Health Surveill. 2020;6:e19199.PubMedPubMedCentral
36.
Zurück zum Zitat Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med. 2020; published online ahead of print. Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med. 2020; published online ahead of print.
37.
Zurück zum Zitat Sen Gupta PS, Biswal S, Singha D, Rana MK. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn. 2020;1–7. Sen Gupta PS, Biswal S, Singha D, Rana MK. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn. 2020;1–7.
38.
Zurück zum Zitat Singh VP, El-Kurdi B, Rood C. What underlies the benefit of famotidine formulations used during COVID-19? Gastroenterology. 2020;S0016–5085(20):35020–4. Singh VP, El-Kurdi B, Rood C. What underlies the benefit of famotidine formulations used during COVID-19? Gastroenterology. 2020;S0016–5085(20):35020–4.
40.
Zurück zum Zitat Ortega JT, Serrano ML, Jastrzebska B. Class A G protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis. Biomolecules. 2020;10:954.PubMedCentral Ortega JT, Serrano ML, Jastrzebska B. Class A G protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis. Biomolecules. 2020;10:954.PubMedCentral
41.
Zurück zum Zitat O’Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol. 2011;128:1153–62.PubMed O’Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol. 2011;128:1153–62.PubMed
42.
Zurück zum Zitat Thangam EB, Jemima EA, Singh H, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets. Front Immunol. 2018;9:1873.PubMedPubMedCentral Thangam EB, Jemima EA, Singh H, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets. Front Immunol. 2018;9:1873.PubMedPubMedCentral
43.
Zurück zum Zitat Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, histamine, mast cells, and mechanisms. Res Sq [Preprint]. 2020; rs.3.rs-30934. Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, histamine, mast cells, and mechanisms. Res Sq [Preprint]. 2020; rs.3.rs-30934.
45.
Zurück zum Zitat Tsuji M. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease. FEBS Open Bio. 2020;10:995–1004.PubMedPubMedCentral Tsuji M. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease. FEBS Open Bio. 2020;10:995–1004.PubMedPubMedCentral
46.
Zurück zum Zitat Tachoua W, Kabrine M, Mushtaq M, Ul-Haq Z. An in-silico evaluation of COVID-19 main protease with clinically approved drugs. J Mol Graph Model. 2020;101:107758.PubMedPubMedCentral Tachoua W, Kabrine M, Mushtaq M, Ul-Haq Z. An in-silico evaluation of COVID-19 main protease with clinically approved drugs. J Mol Graph Model. 2020;101:107758.PubMedPubMedCentral
47.
Zurück zum Zitat Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J. 2020;34:6008–16.PubMed Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J. 2020;34:6008–16.PubMed
52.
Zurück zum Zitat Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents and Chemother. 2020;64:e00819-e820. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents and Chemother. 2020;64:e00819-e820.
56.
Zurück zum Zitat Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sci. 1996;59:PL 365–70. Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sci. 1996;59:PL 365–70.
57.
Zurück zum Zitat Schafer A, Cheng H, Xiong R, et al. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Res. 2018;157:47–56.PubMedPubMedCentral Schafer A, Cheng H, Xiong R, et al. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Res. 2018;157:47–56.PubMedPubMedCentral
58.
Zurück zum Zitat Conti P, Caraffa A, Tetè G, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents. 2020;34 Online ahead of print. Conti P, Caraffa A, Tetè G, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents. 2020;34 Online ahead of print.
59.
Zurück zum Zitat Rabelo K, Gonçalves AJDS, Souza LJ, et al. Zika virus infects human placental mast cells and the HMC-1 cell line, and triggers degranulation, cytokine release and ultrastructural changes. Cells. 2020;9:975.PubMedCentral Rabelo K, Gonçalves AJDS, Souza LJ, et al. Zika virus infects human placental mast cells and the HMC-1 cell line, and triggers degranulation, cytokine release and ultrastructural changes. Cells. 2020;9:975.PubMedCentral
60.
Zurück zum Zitat Ng K, Raheem J, St Laurent CD, et al. Responses of human mast cells and epithelial cells following exposure to influenza A virus. Antiviral Res. 2019;171:104566.PubMed Ng K, Raheem J, St Laurent CD, et al. Responses of human mast cells and epithelial cells following exposure to influenza A virus. Antiviral Res. 2019;171:104566.PubMed
61.
Zurück zum Zitat Portales-Cervantes L, Haidl ID, Lee PW, Marshall JS. Virus-infected human mast cells enhance natural killer cell functions. J Innate Immun. 2017;9:94–108.PubMed Portales-Cervantes L, Haidl ID, Lee PW, Marshall JS. Virus-infected human mast cells enhance natural killer cell functions. J Innate Immun. 2017;9:94–108.PubMed
62.
Zurück zum Zitat Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2016;778:146–51.PubMed Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2016;778:146–51.PubMed
63.
Zurück zum Zitat Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020:eabd2985. Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020:eabd2985.
64.
Zurück zum Zitat Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020:eabd3072. Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020:eabd3072.
65.
Zurück zum Zitat Lippert U, Möller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9:118–24.PubMed Lippert U, Möller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9:118–24.PubMed
66.
Zurück zum Zitat Lichtenstein LM, Gillespie E. Inhibition of histamine release by histamine controlled by H2 receptor. Nature. 1973;244:287–8.PubMed Lichtenstein LM, Gillespie E. Inhibition of histamine release by histamine controlled by H2 receptor. Nature. 1973;244:287–8.PubMed
67.
Zurück zum Zitat Rising TJ, Lewis S. A species comparison of the histamine H2-receptor on mast cells and basophils. Agents Actions. 1982;12:263–7.PubMed Rising TJ, Lewis S. A species comparison of the histamine H2-receptor on mast cells and basophils. Agents Actions. 1982;12:263–7.PubMed
68.
Zurück zum Zitat Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to Il-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205:2887–98.PubMedPubMedCentral Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to Il-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205:2887–98.PubMedPubMedCentral
69.
Zurück zum Zitat Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest. 2001;108:1865–73.PubMedPubMedCentral Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest. 2001;108:1865–73.PubMedPubMedCentral
70.
Zurück zum Zitat Kunzmann S, Mantel PY, Wohlfahrt JG, Akdis M, Blaser K, Schmidt-Weber CB. Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J. 2003;17:1089–95.PubMed Kunzmann S, Mantel PY, Wohlfahrt JG, Akdis M, Blaser K, Schmidt-Weber CB. Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J. 2003;17:1089–95.PubMed
71.
Zurück zum Zitat van der PouwKraan TC, Snijders A, Boeije LC, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998;102:1866–73. van der PouwKraan TC, Snijders A, Boeije LC, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998;102:1866–73.
72.
Zurück zum Zitat Smolinska S, Groeger D, Perez NR, et al. Histamine Receptor 2 is required to suppress innate immune responses to bacterial ligands in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1575–86.PubMed Smolinska S, Groeger D, Perez NR, et al. Histamine Receptor 2 is required to suppress innate immune responses to bacterial ligands in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1575–86.PubMed
73.
Zurück zum Zitat Jafarzadeh A, Nemati M, Khorramdelazad H, Hassan ZM. Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases. Int Immunopharmacol. 2019;70:156–66.PubMed Jafarzadeh A, Nemati M, Khorramdelazad H, Hassan ZM. Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases. Int Immunopharmacol. 2019;70:156–66.PubMed
74.
Zurück zum Zitat Chazot PL, Johnston L, Mcauley E, Bonner S. Histamine and delirium: Current opinion. Front Pharmacol. 2019;10:299.PubMedPubMedCentral Chazot PL, Johnston L, Mcauley E, Bonner S. Histamine and delirium: Current opinion. Front Pharmacol. 2019;10:299.PubMedPubMedCentral
75.
Zurück zum Zitat Cantú TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991;114:1027–34.PubMed Cantú TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991;114:1027–34.PubMed
76.
Zurück zum Zitat Fujii S, Tanimukai H, Kashiwagi Y. Comparison and analysis of delirium induced by histamine H2 receptor antagonists and proton pump inhibitors in cancer patients. Case Rep Oncol. 2012;5:409–12.PubMedPubMedCentral Fujii S, Tanimukai H, Kashiwagi Y. Comparison and analysis of delirium induced by histamine H2 receptor antagonists and proton pump inhibitors in cancer patients. Case Rep Oncol. 2012;5:409–12.PubMedPubMedCentral
77.
Zurück zum Zitat Yamasaki M, Fukuda Y, Tanimoto A, Narahara M, Kawaguchi Y, Ushiroda H, Fukuda S, Murakami T, Maeda Y. Reduction in the rate of postoperative delirium by switching from famotidine to omeprazole in Japanese hepatectomized recipients. J Pharm Health Care Sci. 2019;5:10.PubMedPubMedCentral Yamasaki M, Fukuda Y, Tanimoto A, Narahara M, Kawaguchi Y, Ushiroda H, Fukuda S, Murakami T, Maeda Y. Reduction in the rate of postoperative delirium by switching from famotidine to omeprazole in Japanese hepatectomized recipients. J Pharm Health Care Sci. 2019;5:10.PubMedPubMedCentral
79.
Zurück zum Zitat Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The efficacy of famotidine in improvement of outcomes in hospitalized COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:848.PubMedPubMedCentral Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The efficacy of famotidine in improvement of outcomes in hospitalized COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:848.PubMedPubMedCentral
80.
Zurück zum Zitat Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020;115:1707–15.PubMed Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020;115:1707–15.PubMed
81.
Zurück zum Zitat Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G. Famotidine use is not associated with 30-day mortality: a coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system. Gastroenterology. 2020;12:S0016-5085(20)35249-5. Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G. Famotidine use is not associated with 30-day mortality: a coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system. Gastroenterology. 2020;12:S0016-5085(20)35249-5.
83.
Zurück zum Zitat Yuan S, Wang R, Chan JF, et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020;5:1439–48.PubMed Yuan S, Wang R, Chan JF, et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020;5:1439–48.PubMed
Metadaten
Titel
Histamine receptors and COVID-19
verfasst von
Madeleine Ennis
Katerina Tiligada
Publikationsdatum
18.11.2020
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Inflammation Research / Ausgabe 1/2021
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-020-01422-1

Weitere Artikel der Ausgabe 1/2021

Inflammation Research 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.